Walleye Trading
VYNT

Walleye Trading’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Walleye Trading’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-19
Closed -$22K – 5831
2015
Q3 		$22K Buy
19
+16
+533% +$24.5K ﹤0.01% 4034
2015
Q2 		$6K Buy
+3
New +$4.66K ﹤0.01% 4468

Other funds holding VYNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QGM
Quality Growth Management Rancho Santa Fe, California $88.9M AUM
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Walleye Trading's VYNT Position: Q4 2015 in Review

Walleye Trading sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2015, closing a stake of 19 shares — an estimated $22K sold.

Walleye Trading first reported a position in VYNT in Q2 2015 and held it in 2 quarters. The position peaked at $22K in Q3 2015. 40 funds tracked by Wall St. Rank hold VYNT as of Q4 2015.

  • Walleye Trading reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • Walleye Trading sold 19 Vyant Bio, Inc. Common Stock shares in Q4 2015, an estimated $22K.
  • Walleye Trading first reported a position in Vyant Bio, Inc. Common Stock in Q2 2015 and held it in 2 quarters.
  • Walleye Trading's Vyant Bio, Inc. Common Stock position peaked at $22K in Q3 2015.
  • 40 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2015.

Based on Walleye Trading's 13F filing for Q4 2015, filed 16 Feb 2016.